Advertisement
Loading...

Exelixis, Inc.

EXEL•NASDAQ
Healthcare
Biotechnology
$50.38
$-0.91(-1.78%)
U.S. Market is Open • 10:25

Exelixis, Inc. (EXEL) Stock Overview

Explore Exelixis, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap12.8B
P/E Ratio15.82
EPS (TTM)$3.02
ROE0.40%
Fundamental Analysis

AI Price Forecasts

1 Month$46.75
3 Months$43.61
1 Year Target$55.38

EXEL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Exelixis, Inc. (EXEL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 67.57, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $55.38.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 15.82 and a market capitalization of 12.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.37%
5-Day Change
9.68%
1-Month Change
11.43%
3-Month Change
16.35%
6-Month Change
22.69%
Year-to-Date (YTD) Change
16.59%
1-Year Change
14.45%
3-Year Change
162.05%
5-Year Change
99.92%
All-Time (Max) Change
246.44%

Contact Information

https://www.exelixis.com
650 837 7000
1851 Harbor Bay Parkway, Alameda, CA, 94502

Company Facts

1,147 Employees
IPO DateApr 17, 2000
CountryUS
Actively Trading

Frequently Asked Questions